399 related articles for article (PubMed ID: 28760218)
1. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas.
Pol T; Hijazi Z; Lindbäck J; Alexander JH; Bahit MC; De Caterina R; Eikelboom JW; Ezekowitz MD; Gersh BJ; Granger CB; Hylek EM; Lopes R; Siegbahn A; Wallentin L
Open Heart; 2021 Mar; 8(1):. PubMed ID: 33741689
[TBL] [Abstract][Full Text] [Related]
4. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
[TBL] [Abstract][Full Text] [Related]
5. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
6. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial.
Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
[TBL] [Abstract][Full Text] [Related]
9. Effects of dabigatran according to age in atrial fibrillation.
Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Alings M; De Caterina R; Eikelboom JW; Ezekowitz MD; Held C; Huber K; Hylek EM; Granger CB; Lopes RD; Vinereanu D; Siegbahn A; Wallentin L
JAMA Netw Open; 2020 Sep; 3(9):e2015943. PubMed ID: 32936298
[TBL] [Abstract][Full Text] [Related]
12. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
[TBL] [Abstract][Full Text] [Related]
13. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
[TBL] [Abstract][Full Text] [Related]
14. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
[TBL] [Abstract][Full Text] [Related]
16. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Aulin J; Siegbahn A; Hijazi Z; Ezekowitz MD; Andersson U; Connolly SJ; Huber K; Reilly PA; Wallentin L; Oldgren J
Am Heart J; 2015 Dec; 170(6):1151-60. PubMed ID: 26678637
[TBL] [Abstract][Full Text] [Related]
18. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
19. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
[TBL] [Abstract][Full Text] [Related]
20. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
